Credit Suisse Ag Acelrx Pharmaceuticals Inc Transaction History

Credit Suisse Ag

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$1.03 - $1.7 $16,118 - $26,603	-15,649 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$1.25 - $2.77 $11,343 - $25,137	-9,075 Reduced 36.71%	15,649 $26,000
Q4 2020 Feb 12, 2021	BUY	$1.18 - $1.98 $29,174 - $48,953	24,724 New	24,724 $31,000
Q4 2019 Feb 12, 2020	SELL	$1.66 - $2.4 $31,636 - $45,739	-19,058 Closed	0 $0
Q3 2019 Nov 12, 2019	SELL	$2.1 - $2.87 $12,593 - $17,211	-5,997 Reduced 23.94%	19,058 $42,000
Q2 2019 Aug 14, 2019	BUY	$2.1 - $3.93 $52,615 - $98,466	25,055 New	25,055 $63,000
Q3 2018 Nov 13, 2018	SELL	$2.6 - $4.6 $36,420 - $64,436	-14,008 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$2.13 - $4.2 $12 - $25	6 Added 0.04%	14,008 $47,000
Q1 2018 May 15, 2018	SELL	$1.7 - $2.35 $11 - $16	-7 Reduced 0.05%	14,002 $29,000
Q4 2017 Feb 14, 2018	BUY	$1.75 - $5.5 $24,515 - $77,049	14,009	14,009 $28,000

Ticker ACRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 7,366,600
Market Cap $8.32M
Description
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a pre-programmed ...

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

Stay updated on Credit Suisse Ag with notifications on news.